FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims
This article was originally published in The Rose Sheet
Executive Summary
Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.
You may also be interested in...
ASA Ruling On My Perfect Eyes Reinforces Opportunity For Instant Skin Care
The Perfect Cosmetics Company’s clinical trial evidence is sufficient in the Advertising Standards Authority’s view to support the claim that eye-area wrinkles “virtually disappear” following use of its My Perfect Eyes formula. Products of its ilk could be relatively safe plays from a regulatory perspective in an otherwise challenging category and appeal to younger consumers seeking instant skin-care solutions.
‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection
Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.
FDA: Cosmetic Warning Letters Carry Same Weight Regardless Of Issuing Office
Around 96% of warning letters for excessive cosmetics claims in 2016 have issued from FDA district offices as opposed to CFSAN headquarters, representing a marked shift from previous years. The agency stresses, however, that the source of a warning letter has no bearing on its implications.